We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Swiss health authority, Swissmedic, has approved OSI Pharmaceuticals' Tarceva
for the treatment of patients with locally advanced or metastatic non-small
cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.
Dynavax Technologies has presented data from preclinical models suggesting that
the company's immunostimulatory sequence (ISS)-based anthrax vaccine has the
potential to confer higher levels of immunity quickly and effectively against
the threat of anthrax infection, and may represent a potent new vaccine approach
for anthrax.
Generex Biotechnology has announced that patient enrollment had begun for trials
with a novel therapeutic vaccine for breast cancer developed by its wholly owned
subsidiary Antigen Express.
CytRx, Advanced BioScience Laboratories and the University of Massachusetts
Medical School has completed enrollment of healthy volunteers in a three-arm
Phase I clinical trial for a novel HIV DNA vaccine.
ID Biomedical has completed analysis of data obtained from several Phase I clinical
studies of its Pneumococcal Group-Common Vaccine, PGCvax, in adults, elderly
and toddlers.
Teva Pharmaceutical and Active Biotech AB have announced that the final report of the Phase II study of laquinimod, which was successfully concluded in September 2003, has been published in Neurology.
Cambridge Antibody Technology (CAT) has announced that in its second pivotal
(International Phase III) clinical trial of Trabio failed to meet the primary
endpoint of improving the outcome of surgery for glaucoma.
Researchers have concluded that treatment taken once a day with the investigational
therapy Alvesco significantly improves quality of life compared to placebo in
patients with mild-to-moderate asthma.
Zonagen has received a U.S. patent that covers both compositions of matter and
methods of use for Progenta, which Zonagen is currently developing to treat
uterine fibroids and endometriosis.
ISTA Pharmaceuticals has submitted an investigational new drug application (IND)
with the FDA to conduct a Phase IIb clinical trial for ecabet sodium, a prescription
eye drop for the treatment of dry eye syndrome (keratoconjunctivitis sicca).